USP9YP25

Q-omics provides the consensus-scored USP9YP25 profile across patient tissues and cancer cell-line models. USP9YP25 expression is associated with patient survival in 1 of 34 cancer types, with the highest sampling consensus in STAD. Additionally, USP9YP25 RNA expression shows 13 significant gene co-expression associations, with the highest sampling consensus in STAD. Together, these results highlight STAD as cancer lineages where USP9YP25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.

Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.

Survival associations

This table summarizes USP9YP25 survival associations across molecular data types. USP9YP25 RNA expression shows survival associations in the most cancer types (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.

USP9YP25 data type	Survival analysis	Lineage consensus	Lineage of highest sampling consensus
RNA	Kaplan–Meier	1	STAD (18)	view →

This table ranks reproducible USP9YP25 RNA expression–survival associations across cancer types. High USP9YP25 expression shows unfavorable associations in STAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .017). Together, the overview and detailed table identify STAD as the clearest survival context for USP9YP25 RNA expression.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	III,IV	0.183	0.632	.017	18	view →

Pink = unfavorable, green = favorable. all 1 lineages →

USP9YP25-STAD (OS)

Explore this curve interactively →